Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study

ABSTRACT:Journal ArticleSCOPUS: ar.jinfo:eu-repo/semantics/publishe

Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load

Immune activation and chronic inflammation are recognized as major component of HIV disease even in patients with undetectable viral load. We evaluated the effect of atorvastatin on CD38 activation in such patients, in a case-control study (133 cases - 266 controls). At week 48, CD38 activation was significantly lower in cases vs. controls, with no difference in high-sensitivity C-reactive protein (hsCRP) and CD4. These results suggest that atorvastatin reduces the level of immune activation in patients with undetectable viral load. © 2011 Wolters Kluwer HealthSCOPUS: ar.jinfo:eu-repo/semantics/publishe

Atazanavir has a better impact on lipid profiles than Fosamprenavir and Lopinavir in patients matched baseline triglycerides and cholesterol

info:eu-repo/semantics/nonPublishe

Fosamprenavir boosted with a single 100 mg capsule of Ritonavir as part of a once daily first line regimen in naive patients

info:eu-repo/semantics/nonPublishe

Cardiovascular risk evaluation of HIV-infected patients in a case-control study: comparison of the D:A:D and Framingham equations

info:eu-repo/semantics/nonPublishe

Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico epidemiological study

info:eu-repo/semantics/nonPublishe

Primary HIV infection: Is outcome after treatment interruption influenced by treatment initiation?

info:eu-repo/semantics/nonPublishe

Darunavir in patients who failed on Fosamprenavir: efficacy at week 48

info:eu-repo/semantics/nonPublishe

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5–74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.0SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Comparaison des caractéristiques des patients africains VIH/SIDA initiant un traitement ARV dans le cadre du projet ARV Congo RDC à Lubumbashi

info:eu-repo/semantics/nonPublishe